Summary of findings 5. Intravenous immunoglobulin versus placebo for renal vasculitis in adults.

Intravenous immunoglobulin (IVIg) compared to placebo for renal vasculitis in adults
Patient or population: adults with renal vasculitis Settings: inpatients then outpatients Intervention: IVIg Comparison: placebo
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No. of participants (studies)	Quality of the evidence (GRADE)
	Assumed risk	Corresponding risk
	Placebo	IVIg
Death	118 per 1000	24 per 1000 (1 to 456)	RR 0.20 (0.01 to 3.88)	34 (1)	⊕⊕⊝⊝ low1,2
Kidney function	not reported	not reported	‐‐	‐‐	‐‐
Dialysis	not reported	not reported	‐‐	‐‐	‐‐
Response at 3 months	353 per 1000	822 per 1000 (416 to 1000)	RR 2.33 (1.18 to 4.61)	34 (1)	⊕⊕⊝⊝ low1,2
Relapse at 3 months	267 per 1000	312 per 1000 (104 to 949)	RR 1.17 (0.39 to 3.56)	34 (1)	⊕⊕⊝⊝ low1,2
Adverse events	235 per 1000	706 per 1000 (285 to 1000)	RR 3.00 1.21 to 7.45)	34 (1)	⊕⊕⊝⊝ low1,2
Serious infection	not reported	not reported	‐‐	‐‐	‐‐
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.

¹ Small sample size; single study results
 ² Wide CI